Current Therapy of Chronic Hepatitis C Virus in Treatment-Naive Patients

2019 ◽  
pp. 65-95
Author(s):  
Alhareth AlJuboori ◽  
Satinder Kaur ◽  
Veysel Tahan
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Current Therapy ◽  
Chronic Hepatitis C Virus ◽  
Treatment Naïve

scholarly journals Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

2020 ◽  
Vol 26 (4) ◽  
pp. 554-561
Author(s):  
Desmond Y. H. Yap ◽  
Kevin S. H. Liu ◽  
Yu-Chun Hsu ◽  
Grace L. H. Wong ◽  
Ming-Chang Tsai ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Renal Impairment ◽  
Chronic Hepatitis C ◽  
Severe Renal Impairment ◽  
Asian Patients ◽  
Chronic Hepatitis C Virus ◽  
Treatment Naïve ◽  
Lost To Follow Up

Background/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT) HCV.Methods: We prospectively recruited patients with Child’s A cirrhosis and eGFR <30 mL/min/1.73 m<sup>2</sup> in Hong Kong and Taiwan during 2017–2018 to receive GLE/PIB treatment.Results: Twenty-one patients (GT2, n=7; GT3, n=6; and GT6, n=8) received GLE/PIB for 11.2±1.8 weeks. All except one were treatment-naïve. GLE/PIB was initiated in 16 patients while on dialysis (seven on peritoneal dialysis [PD] and nine on hemodialysis) and in five patients before dialysis. One patient died of PD-related peritonitis during treatment and two were lost to follow up. The SVR12 rate in the remaining 18 patients was 100%. All patients achieved undetectable levels at 4-, 12-, 24- and 48-week after treatment. Patients with deranged alanine aminotransferase showed normalization after 4 weeks and the response was sustained for 48 weeks. No significant adverse event was observed.Conclusions: GLE/PIB treatment was associated with high efficacy and tolerability in HCV-infected patients with severe renal impairment.

scholarly journals Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders

2017 ◽  
Vol 37 (02) ◽  
pp. 127-130 ◽  
Author(s):  
Ingolf Schiefke ◽  
Kerstin Stein ◽  
Thomas Berg ◽  
Ulrike Kullig ◽  
Katrin Ende ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Real Life ◽  
Virologic Response ◽  
Bleeding Disorders ◽  
Chronic Hepatitis C Virus ◽  
Treatment Naïve ◽  
Chronic Hcv

SummaryChronic hepatitis C virus (HCV) infection causes significant mortality in patients with inherited bleeding disorders, however, data of interferon-free antiviral regimes are scarce in this population. Patients, methods: Reallife data of interferon-free therapies of 18 patients with inherited bleeding disorders and chronic HCV genotype 1 infection (94% male, liver cirrhosis Child A/B n = 4/1). Results: Treatment naïve patients were treated for eight weeks with sofosbuvir (SOF)/ledipasvir (n = 3) or for 12 weeks with SOF/ledipasvir (n = 4), SOF/ledipasvir/ribavirin (n = 1), or paritaprevir/r, ombitasvir, dasabuvir (n = 1). Treatment experienced patients without cirrhosis received SOF/ledipasvir (n = 3) or paritaprevir/r, ombitasvir, dasabuvir ± ribavirin (n = 2) for 12 weeks. Re-treated cirrhotic individuals were treated for 24 weeks with SOF/ledipasvir (n = 2) and SOF/daclatasvir (n = 1), or for 12 weeks SOF/simeprevir/1200 mg/d ribavirin (n = 1). Sustained virologic response (SVR-12) was achieved by 17/18 individuals without severe on-treatment side effects. Conclusions: In real-life, HCV-infected patients with inherited bleeding disorders can be effectively and safely treated with interferon- free therapies.

Sign in / Sign up

Export Citation Format

Share Document